Author

Michael Leitner

Boehringer Ingelheim (Germany)Primary ORCID profile (0000-0003-2332-6305 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Michael LeitneriD1 paper · QIMR Berghofer Medical Research Institute

Biology Disciplines

Click to filter author papers

Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Assay:electrophysiology· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Alberto ZingaroiD· 1 shared Caterina BalzottiiD· 1 shared Georg F. RastiD· 1 shared Jazmín Aguado‐SierraiD· 1 shared Mariano Vazquez· 1 shared Noelia Jacobo‐PiquerasiD· 1 shared Paula Dominguez-GomeziD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Alberto ZingaroORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: a loperamide case study

Paula Dominguez-Gomez, Alberto Zingaro, Caterina Balzotti, Michael Leitner, Noelia Jacobo‐Piqueras, Mariano Vazquez, Georg F. Rast, Jazmín Aguado‐Sierra

The paper uses AI-enhanced cardiac digital twins to assess drug proarrhythmic risk by propagating experimental uncertainty and simulating extreme exposures, finding sex-specific arrhythmogenic thresholds for loperamide.

Regulatory Toxicology and Pharmacology · Jun 1, 2026Peer-reviewedBioengineering